Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
EMBC 
Embecta Corp (EMBC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/24/2025: EMBC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $16.67
1 Year Target Price $16.67
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 18.1% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 715.28M USD | Price to earnings Ratio 7.37 | 1Y Target Price 16.67 |
Price to earnings Ratio 7.37 | 1Y Target Price 16.67 | ||
Volume (30-day avg) 5 | Beta 1.06 | 52 Weeks Range 8.99 - 20.24 | Updated Date 12/25/2025 |
52 Weeks Range 8.99 - 20.24 | Updated Date 12/25/2025 | ||
Dividends yield (FY) 5.03% | Basic EPS (TTM) 1.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-25 | When - | Estimate 0.46 | Actual 0.5 |
Profitability
Profit Margin 8.83% | Operating Margin (TTM) 24.85% |
Management Effectiveness
Return on Assets (TTM) 16.59% | Return on Equity (TTM) - |
Valuation
Trailing PE 7.37 | Forward PE - | Enterprise Value 1910606944 | Price to Sales(TTM) 0.66 |
Enterprise Value 1910606944 | Price to Sales(TTM) 0.66 | ||
Enterprise Value to Revenue 1.77 | Enterprise Value to EBITDA 6.72 | Shares Outstanding 59211992 | Shares Floating 56663835 |
Shares Outstanding 59211992 | Shares Floating 56663835 | ||
Percent Insiders 1.46 | Percent Institutions 99.38 |
Upturn AI SWOT
Embecta Corp
Company Overview
History and Background
Embecta Corp. (NYSE: EMBC) was spun off from BD (Becton, Dickinson and Company) on March 1, 2022. It is a global medical technology company focused on diabetes care. The company's history is rooted in the innovation and manufacturing capabilities inherited from BD's diabetes care business.
Core Business Areas
- Diabetes Care Devices: Embecta Corp. designs, manufactures, and distributes a range of diabetes care products, primarily focusing on insulin pens and related delivery systems. This includes pen needles, syringes, and other accessories used by people with diabetes for insulin administration.
Leadership and Structure
Embecta Corp. is led by a management team with experience in the medical device and pharmaceutical industries. The organizational structure is designed to support its global operations, manufacturing, and sales of diabetes care products.
Top Products and Market Share
Key Offerings
- Pen Needles: Embecta Corp. is a leading global manufacturer of pen needles used with insulin pens. These are crucial for patients to inject insulin. Competitors include B. Braun Medical, Artsana S.p.A. (Chicco), and other medical device manufacturers. While specific market share for pen needles is not publicly broken down for Embecta alone, the global diabetes care device market is substantial. Embecta aims to hold a significant portion of the pen needle segment.
- Syringes: The company also offers insulin syringes, though the market is increasingly shifting towards insulin pens. Competitors are similar to those in the pen needle segment.
Market Dynamics
Industry Overview
The diabetes care market is a growing and significant segment of the broader healthcare industry, driven by the increasing prevalence of diabetes globally. This includes a demand for advanced drug delivery devices that improve patient convenience and adherence.
Positioning
Embecta Corp. is positioned as a specialized provider of diabetes care consumables, particularly insulin delivery devices. Its competitive advantage lies in its established manufacturing capabilities, global distribution network inherited from BD, and a focused product portfolio.
Total Addressable Market (TAM)
The global diabetes care market is valued in the tens of billions of dollars, with the insulin delivery device segment representing a significant portion. Embecta Corp. aims to capture a substantial share of the insulin pen needle market, which is a key driver of growth within this TAM.
Upturn SWOT Analysis
Strengths
- Established global manufacturing and distribution network
- Strong brand recognition and legacy from BD
- Focus on a high-demand medical specialty (diabetes care)
- Experienced management team
Weaknesses
- Reliance on a specific product category (pen needles and syringes)
- Potential for disruption from new diabetes management technologies
- Competition from larger, diversified medical device companies
Opportunities
- Growing global prevalence of diabetes
- Expansion into emerging markets
- Development of next-generation insulin delivery devices
- Potential for strategic partnerships or acquisitions
Threats
- Intensifying competition and price pressures
- Regulatory changes affecting medical devices
- Advancements in alternative diabetes treatments (e.g., continuous glucose monitoring, closed-loop systems)
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- B. Braun Medical Inc. (Private)
- Artsana S.p.A. (Private)
- Terumo Corporation (TSE: 4544)
- Ypsomed Group (SIX: YPSN)
Competitive Landscape
Embecta Corp. faces competition from established global players in the medical device industry. Its key advantage lies in its specialized focus and manufacturing scale for pen needles. However, competitors may have broader product portfolios or greater R&D investment in next-generation diabetes technologies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth prior to the spin-off is part of BD's performance. Post-spin-off, growth will be driven by market penetration and new product introductions. (Historical growth figures for the standalone entity to be sourced from financial reports).
Future Projections: Future projections for Embecta Corp. are typically provided by financial analysts covering the company. These projections would consider market trends, competitive landscape, and strategic initiatives. (Analyst estimates to be sourced from financial data providers).
Recent Initiatives: Embecta Corp.'s recent initiatives likely focus on optimizing its manufacturing, expanding its sales channels, and potentially developing new diabetes care delivery solutions. (Specific initiatives to be found in company press releases and investor presentations).
Summary
Embecta Corp. is a focused medical technology company operating in the growing diabetes care market, particularly in insulin delivery devices. Its strengths lie in its manufacturing capabilities and established distribution network. However, it faces significant competition and the risk of technological disruption in its specialized niche. Continued innovation and strategic expansion will be crucial for its long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Embecta Corp. Investor Relations
- SEC Filings (Form 10-K, 10-Q)
- Financial Data Providers (e.g., Bloomberg, Refinitiv, FactSet)
- Industry Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The information is compiled from publicly available sources and may not be exhaustive or entirely up-to-date. Market share data and financial figures are estimates and subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Embecta Corp
Exchange NASDAQ | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2022-04-01 | President, CEO & Director Mr. Devdatt Kurdikar Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1850 | Website https://www.embecta.com |
Full time employees 1850 | Website https://www.embecta.com | ||
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.